🇺🇸 FDA

Intelligence · Patent portfolio

Iovance Biotherapeutics Patents

Full USPTO pharma patent portfolio for Iovance Biotherapeutics — grant dates, expiration, and drug cross-links.

Patents
94
Expiring ≤24m
0

Quick answer

Iovance Biotherapeutics has 94 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Page 2 of 2

  1. US 11273180

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11273181

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11266694

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11254913

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11241456

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11220670

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11202803

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11202804

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11179419

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11168304

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11168303

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11141438

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11141434

    Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof

    Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11123371

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11083752

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11058728

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11052115

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11052116

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11040070

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11026974

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11013770

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11007226

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10953046

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10953047

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10946045

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10946044

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10933094

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10918666

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10894063

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10695372

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10653723

    Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10646517

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10639330

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10537595

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10517894

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10463697

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10420799

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10415015

    Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion

    Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10398734

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10363273

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10272113

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10166257

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10130659

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10004806

    Periodontal regeneration composition and method of using same

    Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9556146

    Lanthionine synthetase C-like 2-based therapeutics

    Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 6670148

    Compositions comprising bioactive peptides prepared without formation of native disulfide bonds

    Expires Mon Dec 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

How many patents does Iovance Biotherapeutics have?

94 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Iovance Biotherapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.